Literature DB >> 17520427

Factors predicting complete necrosis rate after ultrasound-guided percutaneous laser thermoablation of small hepatocellular carcinoma tumors in cirrhotic patients: a multivariate analysis.

G Francica1, G Iodice, M Delle Cave, R Sarrantonio, G Lapiccirella, V Molese, D Smeraldo, F Scarano, F De Marino.   

Abstract

PURPOSE: To assess factors affecting the effectiveness of percutaneous laser ablation (PLA) under ultrasound (US) guidance in terms of complete ablation achievement.
MATERIAL AND METHODS: The clinical records of 86 hepatocellular carcinoma (HCC) tumors (mean diameter 23.7 mm) in 60 cirrhotic patients (mean age 68.3 years; 36 males; 57 HCV+; 53 Child's class A, seven Child's class B) treated by means of PLA were reviewed. PLA was performed with a continuous-wave Nd:YAG laser by a single operator who positioned two to four 300-microm optic fibers advanced in 21-gauge needles into target lesions under US guidance. Triphasic computed tomography (CT) studies were used to verify treatment effectiveness 1 month after PLA completion. The association between characteristics of the lesion and outcome (complete or incomplete ablation) was evaluated by logistic regression, taking into account the following predictive factors: tumor size, pattern of growth (infiltrating or not) at imaging, location, first diagnosis of HCC (naïve tumors vs. non-naïve tumors), number of sessions (1/ > 1), total delivered energy, and years of treatment in 2001-2002 (first period) vs. 2003-2004 (second period).
RESULTS: Complete ablation was obtained in 62 nodules (72%). Statistically significant predictors of incomplete ablation after the first PLA course at both univariate and multivariate analysis included: infiltrating growth pattern (odds ratio (OR) 12.3, P<0.002), non-naïve tumors (OR 8.7, P<0.001), and first period of treatment (OR 10.3, P<0.002).
CONCLUSION: The effectiveness of US-guided PLA for HCC tumors < or =4 cm turned out to be negatively affected by both operator-related (the beginning of the operator's experience with the technique) and tumor-related factors (non-naïve, infiltrating HCC tumors).

Entities:  

Mesh:

Year:  2007        PMID: 17520427     DOI: 10.1080/02841850701199942

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  7 in total

1.  Factors predicting outcomes of microwave ablation of small hepatocellular carcinoma.

Authors:  Anna Maria Ierardi; Francesca Giorlando; Filippo Piacentino; Federico Fontana; Raffaele Novario; Salvatore Alessio Angileri; Ejona Duka; Gianpaolo Carrafiello
Journal:  Radiol Med       Date:  2016-10-15       Impact factor: 3.469

Review 2.  Laser ablation for small hepatocellular carcinoma: State of the art and future perspectives.

Authors:  Giovan Giuseppe Di Costanzo; Giampiero Francica; Claudio Maurizio Pacella
Journal:  World J Hepatol       Date:  2014-10-27

Review 3.  Endoscopic ultrasound guided interventions in the management of pancreatic cancer.

Authors:  Tossapol Kerdsirichairat; Eun Ji Shin
Journal:  World J Gastrointest Endosc       Date:  2022-04-16

4.  Laser ablation for small hepatocellular carcinoma.

Authors:  Claudio Maurizio Pacella; Giampiero Francica; Giovanni Giuseppe Di Costanzo
Journal:  Radiol Res Pract       Date:  2011-12-04

Review 5.  Local ablative treatments for hepatocellular carcinoma: An updated review.

Authors:  Antonio Facciorusso; Gaetano Serviddio; Nicola Muscatiello
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

6.  Innovative approaches for cancer treatment: current perspectives and new challenges.

Authors:  Carlotta Pucci; Chiara Martinelli; Gianni Ciofani
Journal:  Ecancermedicalscience       Date:  2019

7.  Treatment response and preliminary efficacy of hepatic tumour laser ablation under the guidance of percutaneous and endoscopic ultrasonography.

Authors:  Weilu Chai; Qiyu Zhao; Huiming Song; Chao Cheng; Guo Tian; Tian'an Jiang
Journal:  World J Surg Oncol       Date:  2019-08-05       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.